Related Experiment Video

Updated: May 16, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Cannabinoid agonists increase the interaction between β-Arrestin 2 and ERK1/2 and upregulate β-Arrestin 2 and

Jade M Franklin1, Tamara Vasiljevik, Thomas E Prisinzano

  • 1Department of Pharmacology and Toxicology, University of Kansas, 1251 Wescoe Hall Drive, 3048B Malott Hall, Lawrence, KS 66045, United States.

Pharmacological Research
|November 24, 2012
PubMed

Insights

Cannabinoid 2 (CB2) receptor activation increases beta-arrestin 2, enhancing ERK1/2 signaling and upregulating 5-HT2A receptors in the brain. This mechanism may explain adverse effects of cannabinoids and inform therapeutic development.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Cannabinoid 2 (CB2) receptor agonists upregulate 5-HT2A receptors via ERK1/2 signaling in the prefrontal cortex.
  • Elevated 5-HT2A receptor activity is linked to neuropsychiatric disorders like anxiety and schizophrenia.

Purpose of the Study:

  • To investigate the mechanisms underlying CB2 receptor-mediated ERK1/2 activation and 5-HT2A receptor upregulation.
  • To elucidate the role of beta-arrestin 2 in this signaling pathway.

Main Methods:

  • Treatment of Sprague-Dawley rats and a neuronal cell line with cannabinoid agonists and antagonists.
  • Analysis of protein levels (co-immunoprecipitation, Western blot) and mRNA expression.
  • Inhibition of key signaling molecules and cellular processes (clathrin-mediated endocytosis, ERK1/2, AP-1).

Main Results:

  • Sustained CB2 receptor activation enhanced beta-arrestin 2 and pERK levels in rat prefrontal cortex.
  • CB2 receptor agonists upregulated beta-arrestin 2 in neuronal cells, an effect blocked by CB2 antagonists and shRNA.
  • Inhibition of clathrin-mediated endocytosis, ERK1/2, and AP-1 prevented beta-arrestin 2 upregulation.

Conclusions:

  • Sustained CB2 receptor activation enhances beta-arrestin 2 expression, promoting its interaction with ERK1/2 and subsequent 5-HT2A receptor upregulation.
  • The CB2 receptor-mediated beta-arrestin 2 upregulation involves ERK1/2-dependent AP-1 activation.
  • These findings offer insights into adverse cannabinoid effects and potential therapeutic strategies targeting CB2 receptors.

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...